Compare IDXX & CBRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDXX | CBRE |
|---|---|---|
| Founded | 1983 | 1906 |
| Country | United States | United States |
| Employees | N/A | 44000 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 41.5B |
| IPO Year | 1996 | 2001 |
| Metric | IDXX | CBRE |
|---|---|---|
| Price | $521.51 | $139.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $721.67 | $177.86 |
| AVG Volume (30 Days) | 428.9K | ★ 1.1M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.59 | ★ 22.61 |
| EPS | ★ 7.74 | 1.77 |
| Revenue | $4,303,702,000.00 | ★ $40,550,000,000.00 |
| Revenue This Year | $10.88 | $14.31 |
| Revenue Next Year | $8.59 | $9.06 |
| P/E Ratio | ★ $67.38 | $79.72 |
| Revenue Growth | 10.42 | ★ 13.37 |
| 52 Week Low | $500.61 | $121.69 |
| 52 Week High | $769.98 | $174.27 |
| Indicator | IDXX | CBRE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm managed over $155 billion (at year-end 2025) for clients across diverse public and private real estate strategies.